aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
aTyr Pharma presented promising preclinical data for their ATYR2810 antibody at the AACR Annual Meeting 2025 in Chicago. The research focuses on treating glioblastoma multiforme (GBM), an aggressive form of brain cancer.
Key findings show that ATYR2810, which targets neuropilin-2 (NRP2), demonstrated significant anti-tumor activity and improved survival rates in GBM models. The antibody proved effective both as a standalone treatment and when combined with anti-PD-1 therapies.
The research, conducted in collaboration with Stanford Medicine, revealed that ATYR2810 helps combat drug resistance by targeting immunosuppressive myeloid cells in the tumor microenvironment. The study used syngeneic tumor models, including the orthotopic CT-2A mouse model of GBM, showing enhanced anti-tumor immunity and increased overall survival.
aTyr Pharma ha presentato dati preclinici promettenti sul loro anticorpo ATYR2810 durante il AACR Annual Meeting 2025 a Chicago. La ricerca si concentra sul trattamento del glioblastoma multiforme (GBM), una forma aggressiva di tumore cerebrale.
I risultati principali mostrano che ATYR2810, che mira a neuropilina-2 (NRP2), ha dimostrato una significativa attività antitumorale e un miglioramento dei tassi di sopravvivenza nei modelli di GBM. L’anticorpo si è rivelato efficace sia come trattamento singolo sia in combinazione con terapie anti-PD-1.
La ricerca, condotta in collaborazione con Stanford Medicine, ha evidenziato che ATYR2810 aiuta a contrastare la resistenza ai farmaci agendo sulle cellule mieloidi immunosoppressive nel microambiente tumorale. Lo studio ha utilizzato modelli tumorali sinigenici, incluso il modello ortotopico CT-2A nel topo per il GBM, mostrando un potenziamento dell’immunità antitumorale e un aumento della sopravvivenza complessiva.
aTyr Pharma presentó datos preclínicos prometedores sobre su anticuerpo ATYR2810 en la AACR Annual Meeting 2025 en Chicago. La investigación se centra en el tratamiento del glioblastoma multiforme (GBM), una forma agresiva de cáncer cerebral.
Los hallazgos clave muestran que ATYR2810, que se dirige a neuropilina-2 (NRP2), demostró una actividad antitumoral significativa y mejoró las tasas de supervivencia en modelos de GBM. El anticuerpo resultó efectivo tanto como tratamiento único como en combinación con terapias anti-PD-1.
La investigación, realizada en colaboración con Stanford Medicine, reveló que ATYR2810 ayuda a combatir la resistencia a medicamentos al dirigirse a las células mieloides inmunosupresoras en el microambiente tumoral. El estudio utilizó modelos tumorales sinogénicos, incluido el modelo ortotópico CT-2A en ratones para GBM, mostrando una mayor inmunidad antitumoral y un aumento en la supervivencia general.
aTyr Pharma는 시카고에서 열린 AACR Annual Meeting 2025에서 ATYR2810 항체에 대한 유망한 전임상 데이터를 발표했습니다. 연구는 공격적인 뇌암 형태인 교모세포종(GBM) 치료에 초점을 맞추고 있습니다.
주요 결과에 따르면, 신경혈관단백질-2(NRP2)를 표적으로 하는 ATYR2810은 GBM 모델에서 상당한 항종양 효과와 생존율 개선을 보여주었습니다. 이 항체는 단독 치료뿐만 아니라 항-PD-1 치료와 병용 시에도 효과적이었습니다.
스탠포드 의학과 협력하여 진행된 연구는 ATYR2810이 종양 미세환경 내 면역억제성 골수세포를 표적으로 하여 약물 저항성을 극복하는 데 도움을 준다는 것을 밝혔습니다. 연구는 동종이식 종양 모델, 특히 GBM의 정위 CT-2A 마우스 모델을 사용하여 항종양 면역 반응 강화와 전체 생존율 증가를 입증했습니다.
aTyr Pharma a présenté des données précliniques prometteuses sur leur anticorps ATYR2810 lors du AACR Annual Meeting 2025 à Chicago. La recherche porte sur le traitement du glioblastome multiforme (GBM), une forme agressive de cancer du cerveau.
Les résultats clés montrent qu’ATYR2810, ciblant la neuropiline-2 (NRP2), a démontré une activité antitumorale significative et une amélioration des taux de survie dans des modèles de GBM. L’anticorps s’est avéré efficace à la fois en traitement seul et en association avec des thérapies anti-PD-1.
La recherche, menée en collaboration avec Stanford Medicine, a révélé qu’ATYR2810 aide à combattre la résistance aux médicaments en ciblant les cellules myéloïdes immunosuppressives dans le microenvironnement tumoral. L’étude a utilisé des modèles tumoraux syngéniques, y compris le modèle orthotopique CT-2A de souris pour le GBM, montrant une immunité antitumorale renforcée et une survie globale accrue.
aTyr Pharma präsentierte vielversprechende präklinische Daten zu ihrem Antikörper ATYR2810 auf dem AACR Annual Meeting 2025 in Chicago. Die Forschung konzentriert sich auf die Behandlung von Glioblastoma multiforme (GBM), einer aggressiven Form von Hirntumor.
Wesentliche Erkenntnisse zeigen, dass ATYR2810, das auf Neuropilin-2 (NRP2) abzielt, eine signifikante antitumorale Wirkung und verbesserte Überlebensraten in GBM-Modellen zeigte. Der Antikörper erwies sich sowohl als Monotherapie als auch in Kombination mit Anti-PD-1-Therapien als wirksam.
Die in Zusammenarbeit mit Stanford Medicine durchgeführte Forschung zeigte, dass ATYR2810 hilft, die Medikamentenresistenz zu bekämpfen, indem es immununterdrückende myeloide Zellen im Tumormikroumfeld gezielt angreift. Die Studie verwendete syngene Tumormodelle, einschließlich des orthotopen CT-2A-Mausmodells für GBM, und zeigte eine verstärkte antitumorale Immunität sowie eine erhöhte Gesamtüberlebensrate.
- ATYR2810 demonstrated significant anti-tumor activity in preclinical GBM models
- Drug showed enhanced efficacy when combined with anti-PD-1 therapy
- Positive survival rate increase in GBM model trials
- Research collaboration with Stanford Medicine strengthens clinical development pipeline
- Potential new approach for treating drug-resistant cancers through NRP2 targeting
- Still in preclinical stage, indicating long pathway to potential commercialization
- No human trial data available yet
- Facing competition in crowded immunotherapy market
Insights
ATYR2810 shows promising anti-tumor activity in glioblastoma model, combating immunosuppression mechanisms that limit current therapies' effectiveness.
The preclinical data for ATYR2810 targeting neuropilin-2 (NRP2) demonstrates significant anti-tumor activity in a glioblastoma multiforme (GBM) model, one of the most aggressive brain cancers with notoriously poor treatment options. What's mechanistically compelling is ATYR2810's ability to modulate immunosuppressive myeloid cells in the tumor microenvironment - a key resistance factor that has hindered immunotherapy efficacy in GBM.
The dual efficacy profile - both as monotherapy significantly increasing overall survival and enhancing anti-PD-1 checkpoint inhibitor effectiveness - represents a versatile therapeutic approach. This synergistic effect with checkpoint inhibitors is particularly important since immunotherapies alone have shown limited success in GBM due to the immunosuppressive microenvironment.
The orthotopic CT-2A mouse model used in this research is notable for its high prevalence of myeloid-derived suppressor cells with enriched NRP2 expression, making it highly relevant for assessing ATYR2810's mechanism. By reversing the immunosuppressive function of these cells, ATYR2810 appears to restore anti-tumor immunity in a particularly challenging cancer model.
Positive preclinical data strengthens aTyr's oncology pipeline, showing ATYR2810's efficacy against glioblastoma both alone and with checkpoint inhibitors.
These preclinical findings represent meaningful advancement for aTyr's oncology pipeline, establishing proof-of-concept for their NRP2-targeting antibody ATYR2810 in glioblastoma multiforme. GBM represents a substantial unmet medical need with poor prognosis and limited therapeutic options, making any promising new approach particularly valuable.
The data demonstrates two critical advantages: efficacy as monotherapy and enhanced effect in combination with anti-PD-1 therapy. This versatility potentially positions ATYR2810 as both a standalone treatment and a combination agent that could enhance existing immunotherapies - an important commercial consideration in the increasingly combination-focused immuno-oncology landscape.
The targeting of NRP2 represents a differentiated mechanism compared to other approaches in the immunotherapy space. By specifically modulating myeloid-derived suppressor cells, ATYR2810 addresses a key resistance mechanism in the tumor microenvironment. The collaboration with Stanford Medicine adds scientific credibility to these findings, though investors should recognize these remain early preclinical results with clinical validation still ahead.
Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present a poster featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the American Association for Cancer Research (AACR) Annual Meeting 2025, which is being held April 25 – 30, 2025, in Chicago, IL.
“Aggressive cancers like glioblastoma multiforme (GBM) continue to show drug resistance, and the efficacy of current immunotherapies may be limited due to immunosuppressive myeloid cells in the tumor microenvironment that contribute to drug resistance. We are pleased to see that ATYR2810 appears to combat drug resistance mechanisms, and we are particularly encouraged by its ability to increase survival and improve the effectiveness of checkpoint inhibitors in a GBM model,” said Leslie A. Nangle, Ph.D., Vice President, Research, at aTyr. “These findings, which were generated as part of our ongoing research collaboration with Dr. Michael Lim and Stanford Medicine, demonstrate the role of NRP2 in maintaining the immunosuppressive tumor microenvironment and suggest that blocking NRP2 may offer a new approach to treating GBM, both as a monotherapy and in combination with anti-PD-1 therapies.”
Details of the poster presentation appear below. The poster will be available on the aTyr website once presented.
Title: Immunosuppressive myeloid cells can be modulated with NRP2-targeting antibody ATYR2810 leading to enhanced anti-tumor immunity
Authors: Christoph Burkart, Clara Polizzi, John Choi, Max Pastenes, Alison Barber, Michael Lim, Leslie Nangle. aTyr Pharma, San Diego. Department of Neurosurgery, Stanford School of Medicine, Stanford.
Session: Antibodies and Antibody-Drug Conjugates
Poster Number: 27
Date and Time: Tuesday, April 29, 2025 from 9:00AM – 12:00PM CT
Location: Poster Board Section 36, McCormick Place Convention Center, Chicago, IL
The poster presents preclinical research evaluating the use of ATYR2810 in syngeneic tumor models including the orthotopic CT-2A mouse model of GBM, which has a high prevalence of myeloid-derived suppressor cells that exhibit enriched expression of NRP2 and promote an immunosuppressive tumor microenvironment. The findings demonstrate that ATYR2810 when used as a single agent enhanced anti-tumor immunity and resulted in a significant increase in overall survival. Additionally, when combined with an anti-PD-1 agent, ATYR2810 further increased survival and reduced tumor size. These findings suggest that modulating NRP2 may offer a new approach to reversing the immunosuppressive function of myeloid cells in the tumor microenvironment.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipate," “believes,” “could,” “can,” “designed,” “expects,” “intends,” “may,” “plans,” “potential,” “suggest,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the potential therapeutic benefits and applications of NRP2 antibodies, including ATYR2810 as a new approach to targeting cancers; timelines and plans with respect to certain research and development activities; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of of product candidates (including the risk that future findings do not support the findings described in the poster), the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What are the key findings of ATYR2810 in glioblastoma cancer treatment presented at AACR 2025?
How does ATYR2810 combat drug resistance in brain cancer treatment?
When and where will ATYR present their ATYR2810 cancer research findings?
What makes ATYR2810's approach unique in treating glioblastoma multiforme?
What is the significance of ATYR's collaboration with Stanford Medicine for ATYR2810?
